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Abstract
Importance: Disease burden data helps guide research prioritization.
Objective: To determine the extent towhich grants issued by theNational Institute of Arthritis andMusculoskeletal and Skin Diseases
(NIAMS) reflect disease burden, measured by disability-adjusted life years (DALYs) from Global Burden of Disease (GBD) 2010 project.
Design: Two investigators independently assessed 15 skin conditions studied by GBD 2010 in the NIAMS database for grants
issued in 2013. The 15 skin diseases were matched to their respective DALYs from GBD 2010.
Setting: The United States NIAMS database and GBD 2010 skin condition disability data.
Main Outcome(s) and Measure(s): Relationship of NIAMS grant database topic funding with percent total GBD 2010 DALY
and DALY rank for 15 skin conditions.
Results: During fiscal year 2013, 1,443 NIAMS grants were issued at a total value of $424 million. Of these grants, 17.7% covered
skin topics. Of the total skin disease funding, 82% (91 grants) were categorized as ‘‘general cutaneous research.’’ Psoriasis, leprosy,
and ‘‘other skin and subcutaneous diseases’’ (ie; immunobullous disorders, vitiligo, and hidradenitis suppurativa) were over-
represented when funding was compared with disability. Conversely, cellulitis, decubitus ulcer, urticaria, acne vulgaris, viral skin
diseases, fungal skin diseases, scabies, and melanoma were under-represented. Conditions for which disability and funding
appeared well-matched were dermatitis, squamous and basal cell carcinoma, pruritus, bacterial skin diseases, and alopecia areata.
Conclusions and Relevance: Degree of representation in NIAMS is partly correlated with DALY metrics. Grant funding was
well-matched with disability metrics for five of the 15 studied skin diseases, while two skin diseases were over-represented
and seven were under-represented. Global burden estimates provide increasingly transparent and important information
for investigating and prioritizing national research funding allocations.
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Introduction
The 2010 Global Burden of Disease Study (GBD 2010)
synthesizes data from 187 countries covering 291 diseases and
injuries, 1160 sequelae, and 67 risk factors from 1990 to 2010 [1].
GBD 2010 measures disease burden in disability-adjusted life years
(DALYs), a population health metric that combines mortality and
morbidity by summing years of life lost and years lived with
disability into one numerical value [2,3]. Greater internal validity
and compass distinguish GBD 2010 from previous work [2].
Research programs, policy makers, and healthcare providers all
face the dilemma of fairly allocating limited resources [4,5]. These
stakeholders use data and criteria driven processes to determine
priorities and reduce knowledge gaps [2,6]. Epidemiological
information and disease burden estimates contribute to these
efforts.
The National Institute of Arthritis and Musculoskeletal and Skin
Diseases (NIAMS), a division of the National Institutes of Health
(NIH), supports research on the cause, treatment, and prevention
of diseases of the bones, joints, muscles, and skin with US taxpayer
dollars allocated from Congressional appropriations [7–9]. The
skin focus of NIAMS research ranges from common diseases that
affect millions of persons, such as eczema and psoriasis, to rare and
overlooked diseases, such as pachyonychia congenita [7,9].
Multifaceted and complex processes including expert and public
comment guide NIAMS research priority setting, and a compet-
itive peer-review system identifies the highest caliber research with
the most potential [6]. This study compares current NIAMS
funding of skin-focused research with skin disease burden
estimated by GBD 2010.
Methods
Fifteen skin conditions were studied by GBD 2010 under the
umbrella category of skin and subcutaneous diseases: dermatitis
(including eczema), acne vulgaris, bacterial skin diseases, viral
skin diseases, urticaria, fungal skin diseases, pruritus, scabies,
alopecia areata, cellulitis, decubitus ulcer, melanoma, psoriasis,
squamous and basal cell carcinoma, and leprosy. In this study,
squamous and basal cell carcinoma are collectively referred as
non-melanoma skin cancer (NMSC). GBD 2010 also included an
other skin and subcutaneous diseases category (see Table 1 for ICD-10
category definitions).
All data were extracted independently by two authors (CK and
LB) from January to February 2014 with consensus review by
senior author (RPD) to resolve discrepancies. Grants awarded by
NIAMS in 2013 were obtained online at http://report.nih.gov/
award/index.cfm, by selecting ‘‘2013’’ for the fiscal year and
‘‘NIAMS’’ for the institute/center. Grant titles and abstracts were
examined and categorized to determine if they focused on a skin
condition. Skin-focused grants were selected and further classified
(see categories listed in Table 1). The predominant focus and aim
of the grant was used to determine its categorization. Isolated
terms mentioned solely as project terms, application, or public health
relevance were not used to guide categorization. Title and abstract
terms leading to inclusion of the grant under one of the 15 skin
conditions or the other skin and subcutaneous diseases category are
defined in Tables S2 and S3 in File S1. Broad scientific themes of
skin grant proposals, regardless of specific disease focus, were
classified as basic science or clinical research (subcategories: etiology,
prevention, detection/diagnosis/treatment) (see Table S1 in File S1).
Grants were also placed into several additional categories not used
by GBD 2010 including: training & department/institution
program, conference, general cutaneous research, and miscella-
neous (see Table S4 in File S1 for specific inclusion terms). The
general cutaneous research category includes grants that lack a specific
disease focus and the miscellaneous category includes dermatologic
conditions not categorized by GBD 2010. If grants were assigned
to more than one category, the grant amount was divided equally
between the categories when summing funding totals. Grants with
the same title but differing amounts of funding were counted
separately but denoted by an asterisk (Table S1 in File S1).
Grants focusing on systemic conditions that also have skin
manifestations were excluded, such as systemic sclerosis, systemic
lupus erythematosus, and dermatomyositis. These three conditions
are included under the GBD category of musculoskeletal diseases.
However, variants of cutaneous lupus (discoid and subacute
cutaneous lupus) were included in the other skin and subcutaneous
disease category. Grants on wound healing were excluded since
wound healing disability is not included as a skin condition by
GBD.
The number of grants and proportion of NIAMS funding for
each of the 15 skin diseases were matched to their respective
disability, measured in disability-adjusted life years (DALYs). One
DALY is equivalent to one lost year of healthy life [1]. Methods
used by the GBD project to generate these disability estimates as
well as GBD 2010 ICD-10 and ICD-9 code definitions for each
disease have been previously described [10–12]. DALY metrics,
expressed as percent of total US DALYs of all 291 conditions
measured in GBD 2010, were obtained from the GBD Compare
interactive time plot [13] Using this tool, we selected search
parameters of ‘time plot,’ ‘DALYs’ metric, ‘United States’ place,
‘all ages,’ ‘both’ sexes, and ‘%’ units for each skin condition.
Matching was accomplished by creating a data plot of funding
versus disability to generate a linear line of best fit with correlation
coefficient, and qualitatively determining those conditions that
were well-matched or not well-matched.
This study did not involve human subjects, thus institutional
review board approval was not necessary.
Results
During fiscal year 2013, NIAMS issued 1,443 grants at a total
value of $424 million, constituting 1.9% of the $22.5 billion issued
for total grant funding by the NIH in 2013. Coincidentally, the
overarching category of ‘‘skin and subcutaneous diseases’’
accounted for 1.9% of total US disability measured in GBD
2010. Amongst the 1,443 NIAMS grants, 256 grants (17.7%)
pertained to skin topics, comprising $73.3 million (17.3% of total
NIAMS funding in 2013) (Table S1 in File S1 for skin grant titles
and categorization). The category of general cutaneous research
comprising grants without a specific disease focus, received
36.0% of total skin funding and 90 grants. Comparing disability
and funding, leprosy, psoriasis, and other skin and subcutaneous diseases
demonstrated over-representation (Figures 1 and 2). Conversely,
cellulitis, decubitus ulcer, urticaria, acne vulgaris, viral skin
diseases, fungal skin diseases, scabies, and melanoma were
under-represented. Conditions for which disability and funding
appeared well-matched were dermatitis, NMSC, pruritus, bacte-
rial skin diseases, and alopecia areata. Approximately 4.7% of
skin-focused grants (n = 12) were assigned to more than one
category.
Of the 15 specific GBD skin conditions, NMSC had the greatest
representation (7.8% of total skin funding, 24 grants), which was
well-matched with its second greatest US burden estimate (0.28%
of total US DALY) (Table 1). Dermatitis had the greatest burden
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estimate of the 15 skin diseases (0.48% of total US DALY), ranking
as the most disabling skin disease studied by GBD 2010.
Dermatitis received the second greatest amount of funding of
the 15 skin conditions (6.4% of total skin funding, 14 grants),
followed by psoriasis (6.2%, 19 grants), pruritus (3.3%, 10 grants),
and leprosy (3.1%, 3 grants).
Interestingly, acne vulgaris caused the 4th greatest US skin
disability (0.25% of total US DALYs) but received less funding
(0.7% of total skin funding, 4 grants) than the 13th most disabling
category, bacterial skin diseases (1.8% of total skin funding, 7
grants. Similarly, melanoma was responsible for the 3rd greatest
US skin disability (0.27%) but received only 2.3% of total NIAMS
skin funding (Table 1).
Of note, urticaria, decubitus ulcer, and alopecia areata were
each represented by one grant and received 0.3%, 0.2%, and
0.5% of total skin funding, respectively. Disability metrics for these
three conditions were 0.14%, 0.1%, and 0.071% of total US
DALYs, respectively. Conversely, while leprosy had the lowest US
DALY of the GBD 2010 skin conditions and accounted for a scant
amount of the total US burden (0.0000034% of total US DALYs),
the condition received 3.1% of total skin funding (3 grants). To put
this in perspective, leprosy funding is similar to that of the 5th most
disabling skin disease, pruritus, which received 3.3% of total skin
funding. GBD skin conditions with no grant funding or
representation were viral skin diseases (0.15% of total US DALYs,
DALY rank 9 of 15), fungal skin diseases (0.086%, rank 9),
cellulitis (0.057%, rank 12), and scabies (0.029%, rank 14).
Eleven diseases within the umbrella other skin and subcutaneous
diseases category had greater NIAMS representation (13.1% total
skin funding, 44 grants) than any of the 15 individual GBD skin
conditions (Table 2). This other category was more disabling than
all studied skin conditions (0.29% of total US DALYs), with the











US DALYc 2010 Absolute
Numberd (Percent of total







L20–L28 4,657,679.75 (6.35) 14 390,233 (0.48) 1
Non-melanoma skin
cancer
C44, D04 5,750,690.5 (7.84) 24 230,918 (0.28) 2
Melanoma C43, D03, D48.5 1,716,496.5 (2.34) 8 220,168 (0.27) 3
Acne vulgaris L70 528,722.25 (0.72) 4 205,356 (0.25) 4
Pruritus L29 2,435,743 (3.32) 10 134,569 (0.16) 5
Viral skin diseases B00, B07–B09 0 0 116,972 (0.15) 6
Urticaria L50 193,016 (0.26) 1 108,983 (0.14) 7
Decubitus ulcer L89 156,387 (0.21) 1 84,763 (0.1) 8
Fungal skin diseases B35, B36.0, B36.1, B36.2,
B36.3, B36.8, B36.9
0 0 70,655 (0.086) 9
Psoriasis L40–L41 4,558,347 (6.22) 19 64,342 (0.078) 10
Alopecia areata L63.0, L63.1, L63.8, L63.9 362,137 (0.49) 1 58,662 (0.071) 11
Cellulitis L03.0, L03.1, L03.2–L03.9 0 0 46,772 (0.057) 12
Bacterial skin diseases L00, L01, L02, L04, L08,
L88,L97, L98.0–L98.4
1,332,962 (1.82) 7 42,745 (0.054) 13
Scabies B66 0 0 24,109 (0.029) 14
Leprosy A30, B92 2,290,832 (3.12) 3 2.77 (0.0000034) 15
Other skin and
subcutaneous diseases
B85, B87, B88, L05.0, L05.9,
L10–L13, L28, L30, L42–L44, L51,
L52–L53, L55–L60, L64–L68,
L71–L75, L80–L85, L87, L90–L92,
L93, L94–L95
9,612,761 (13.11) 44 240,645 (0.29) N/Af
General cutaneous
research
N/A 26,371,614 (35.96) 90 N/A N/A
Conference N/A 267,366 (0.36) 12 N/A N/A
Training & department/
institute program
N/A 7,391,817 (10.08) 22 N/A N/A
Miscellaneous N/A 5,708,836 (7.78) 10 N/A N/A
aSee reference 11.
bOnly for fiscal year 2013; total funding for all NIAMS skin categories is $73,335,407.
cAll ages.
dRounded to the nearest integer.
eOut of the 15 skin disease categories studied by GBD 2010.
fN/A = not available.
doi:10.1371/journal.pone.0102122.t001
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exception of dermatitis. Within the other skin and subcutaneous diseases
category, the immunobullous disorders (pemphigoid and pemphi-
gus) received the greatest amount of total skin funding (4.9%),
followed by vitiligo with 2.4% of total skin funding. Compara-
tively, the disabling but more common disease, hidradenitis
suppurativa, received the lowest skin funding (0.1% of total skin
funding, 1 grant).
Twelve and 22 grants were devoted to conferences and training
& department/institute programs, respectively (Table 1). Despite
the high quantity of grant representation, only 0.4% of total skin
funding was allocated to conferences while a larger proportion of
10.1% was allocated to training & department/institute programs.
The miscellaneous category received 7.8% of total skin funding (10
grants) covering six skin conditions: pachyonychia congenita, port-
wine stain, hemangioma, melanocytic nevi, and vesicant-induced
skin injury.
Looking at broad scientific themes of grant proposal design,
approximately 82 percent of skin-based NIAMS funding (209
grants) in 2013 was allocated to basic science grants. The remaining
47 non-basic science grants were clinical research grants
investigating etiology (2 grants), prevention (3), and detection/
diagnosis/treatment development (9), or devoted to training
programs (13), establishment of research/CORE centers (8), or
conferences (12) (Table 3).
Discussion
Diseases for which NIAMS funding exceeded associated
disability
Funding allocated to psoriasis, leprosy, and other skin and
subcutaneous diseases over-matched the conditions’ disability. Psori-
asis is the most common autoimmune disease in the United States,
affecting an estimated 7.5 million Americans [14]. Thus, while
psoriasis’ DALY was the sixth lowest amongst the 15 GBD skin
conditions, it is not simply a skin problem. It has been shown to be
an independent risk factor for cardiovascular disease and
metabolic syndrome [15]. Psoriasis is responsible for an estimated
11.25 billion dollars in annual direct and indirect health care costs
[16]. Many of the psoriasis NIAMS grants focused on study of the
immune system for treatment options, correlating well with the
evolution of novel treatment approaches over the past decade that
target psoriasis’ mechanistic origin in the immune system [17].
The three NIAMS grants included under leprosy are focused on
the immunobiological aspects of leprosy. Although leprosy is
scarce within the US, the condition remains endemic in regions of
Angola, Brazil, the Central African Republic, India, Madagascar,
Nepal and the United Republic of Tanzania and in previously
highly endemic countries, such as the Democratic Republic of the
Congo and Mozambique [18,19]. Potential reasons for the
apparent over-representation of NIAMS funds allocated to leprosy
include contribution to global efforts for leprosy eradication,
Figure 1. NIAMS skin funding in 2013 and skin disease disability bar graph—Distribution of NIAMS funding in 2013 for skin-related
grants (red) compared to percent of total US GBD 2010 DALYs for each category (blue).
doi:10.1371/journal.pone.0102122.g001
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improvement of the US image abroad, applicability to other
diseases, convenience of leprosy as a scientific model, and cultural
implications of the disease [20–23].
While disability estimates are not available for the individual
diseases in the other skin and subcutaneous diseases category, a curious
hierarchy of funding exists. The greatest amount of funding in this
category was devoted to the rare, autoimmune immunobullous
Figure 2. NIAMS skin funding in 2013 compared to skin disease disability scatter plot–GBD 2010 skin condition category NIAMS
2013 grant funding versus US GBD 2010 skin condition DALYs.
doi:10.1371/journal.pone.0102122.g002
Table 2. Conditions represented from the ‘‘other skin and subcutaneous diseases’’ Global Burden of Diseases category in the
NIAMS 2013 skin-focused grantsa (arranged in order of decreasing funding).
Skin Condition Fundingb (Percent) Number of Grants
Immunobullous disorders 3,623,922.5 (4.94) 12
Vitiligo 1,739,205.5 (2.37) 8
Other epidermal thickening 1,616,370 (2.20) 5
Skin changes due to chronic exposure to nonionizing radiation 508,893.5 (0.69) 4
Hypertrophic disorders of skin 611,925 (0.83) 3
Lupus erythematosus 575,715 (0.79) 4
Primary cicatricial and scarring alopecia 458,442 (0.63) 2
Androgenic alopecia 59,339.25 (0.08) 1
Hypertrichosis 59,339.25 (0.08) 1
Other localized connective tissue disorders 276,959 (0.38) 3
Hidradenitis suppurativa 82,650 (0.11) 1
aSee reference 11.
bOnly for fiscal year 2013; total funding for all NIAMS skin categories is $73,345,407.
doi:10.1371/journal.pone.0102122.t002
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disorders (pemphigoid and pemphigus). Vitiligo and other
epidermal thickening followed with the second and third greatest
funding dollars, respectively. Grant research proposals for these
conditions focus heavily on pathogenesis and treatment. The least
amount of funding in this category was allocated to hidradenitis
suppurativa (HS). NIAMS funded one grant on treatment for HS,
a common problem involving inflammation of the follicular
epithelium that causes significant impact on quality of life [24].
Diseases for which NIAMS funding proportion fell short
of associated disability
In contrast to leprosy and psoriasis, acne vulgaris received
disproportionately low funding compared to disability. Acne
vulgaris is a very common skin diagnosis in the United States,
affecting both teenagers and adults with a national price tag of 2.5
billion dollars [25]. A recent study revealed the need for large,
randomized, controlled trials for acne treatment comparative
effectiveness as well as the establishment of acne vulgaris standard
treatment recommendations and training programs for medical
students and residents [26]. Perhaps acne vulgaris is an area for
future expansion in NIAMS-funded research.
Viral skin diseases, fungal skin diseases, scabies, and cellulitis
were all uniformly under-represented by NIAMS. These infectious
etiologies may be represented in the NIH infection branch, the
National Institute of Allergy and Infectious Diseases (NIAID).
However, the NIAMS specifically delineates that ‘‘studies of
microbe-host interactions and of diseases triggered by bacterial,
viral, or fungal infections, such as leprosy, acne, and post-herpetic
neuralgia’’ are within their established funding research areas [27].
Basic science focus
Over 80 percent of skin-based NIAMS funding (209 grants) in
2013 was allocated to basic science grants. The NIAMS does
explicitly delineate basic science as ‘‘the foundation for tomorrow’’
as well as the importance of industry in ‘‘conducting basic
research, developing new technologies, and commercializing
federally supported discoveries’’ in their 2014 Statement to the
Senate Appropriations Subcommittees [8]. While the NIAMS
institutional focus has largely been on understanding the
‘‘molecular bases of about 4,000 diseases,’’ recent efforts have
shifted to translate basic science discoveries to clinical applicability
[28].
Strengths and limitations
A 1999 cross-sectional study compared funding by the National
Institutes of Health with burden of disease [29]. In response, NIH
director Harold Varmus noted that ‘‘advocacy groups have
tended, understandably, to focus their attention on alleged
inequities between the toll of a specific disease and spending for
research on that disease,’’ and further explained that ‘‘these claims
are of great concern to the NIH, because they threaten to
undermine the agency’s credibility, and to Congress, because they
challenge its oversight in a politically sensitive arena’’ [30]. The
results of our study are not meant to criticize the funding levels of
particular diseases. Instead the goal of our exploratory investiga-
tion is to examine how the most advanced method of measuring
disease disability from GBD 2010 may potentially contribute to
the multifaceted and complex funding prioritization. As Dr.
Varmus further stated, ‘‘it is important to emphasize that there is
not—and should not be—an absolute correspondence [between
burden of disease and spending patterns]’’ [30].
The current study acknowledges the following limitations.
NIAMS is one of 27 institutes and centers under the NIH, each
devoted to specified areas of biomedical science. While percent
funding shared between NIAMS and other NIH institutes would
be informative, this data is not readily available. For instance,
melanoma was included in the present study, however it should be
noted that melanoma funding is shared between NIAMS and
another NIH center, the National Cancer Institute (NCI) [31]. A
future study investigating cancer funding, including melanoma,
may be useful and informative.
The current study examined only grants issued by the NIAMS
in fiscal year 2013. The 2013 Budget Control Act, also know as
sequestration, had significant impact on the NIH, including the
NIAMS, causing mandatory budgets cuts that resulted in a 5.6
percent decrease in the 2013 NIAMS budget ($505 million) [32].
Government shutdown in October 2013 led the NIH to
temporarily furlough more than 75 percent of its employees and
delay more than 200 grant review meetings across the NIH,
resulting in decreased new and old grants awarded [32]. When
money is tight, priorities naturally present themselves. Economic
hardships such as the sequestration in 2013 allow a unique look
into true research prioritization by a national research center.
The subjective nature of grant categorization must be
mentioned. An objective and much easier method would involve
inclusion of any grant that mentions a certain disease at least once
in the title, abstract, or project terms under that particular disease
category. However, it is common for a disease to be mentioned
once as a project term or in the ‘public health relevance’ of the
abstract but not part of the actual proposed research aims or
methods. Thus, until more sophisticated search and categorization
systems become available, categorization methods explained in the
methods section are most appropriate. Finally, it should be noted
that in general, NIH Institutes fund the ‘‘best science’’ and it is
possible that under-represented areas were the result of proposals
that did not meet funding criteria.
Table 3. Broad scientific themes of NIAMS 2013 skin grants in percentage.
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Conclusions
This study mapped disability metrics from the GBD Study to
research funded by the NIAMS. Burden of disease data appear to
inform NIAMS prioritization, particularly for dermatitis, NMSC,
pruritus, bacterial skin diseases, and alopecia areata. Multiple
criteria including infrastructure and quality of research design,
opportunity for scientific innovation, cost benefit, influence on
vulnerable or neglected populations, interest group advocacy,
disease transmissibility, public and patient impact, and predictions
of future impact influence research funding. NIH funding is
guided by the collaborative efforts of numerous agencies such as
the Centers for Disease Control and Prevention, Department of
Veterans Affairs, Department of Defense, and pharmaceutical
industries. As the GBD database begins updating annually, ‘real-
time’ information will be available for burden of disease in global
and country-specific populations. While burden of disease should
not serve as the sole factor determining funding allocation, funders
should be aware of the burden of different skin diseases to inform
and enhance a public discussion and optimize research prioriti-
zation.
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